Sunday 18 October 2026
Export IGC’s income statement to Excel — free account
IGC Pharma, Inc.
IGC Pharma, Inc.’s revenue for fiscal 2025 (year ended March 2025) was $1.3 million, down 5.50% from fiscal 2024. In the quarter to June 2026, revenue fell 19.7%, EPS fell 100.0%, free cash flow fell 103.3% and total debt rose 713.5%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.
0.25
0.00
0.00%
Follow IGC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | — | 0.00 | 0.00 |
P/S ratio |
34.35 | — | 21.89 | 24.60 | |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | |
P/Operating CF |
(27.94) | — | (20.87) | (20.07) | |
P/B ratio |
4.70 | — | 4.17 | 4.42 | |
Price to Tangible BV |
11.82 | — | 29.92 | 43.34 | |
EV/Sales |
33.57 | — | 22.47 | 25.27 | |
EV/EBITDA |
0.00 | — | 0.00 | 0.00 | |
EV/Operating CF |
(7.71) | — | (5.55) | (5.21) | |
EV/FCF |
(7.68) | — | (5.56) | (4.89) | |
Quick Ratio |
0.77 | 0.44 | 0.09 | 0.13 | |
Current Ratio |
1.32 | 0.83 | 0.40 | 0.39 | |
Net Debt/EBITDA |
0.34 | 0.00 | (0.28) | (0.27) | |
Debt/Assets |
1.35% | 3.20% | 9.98% | 11.39% | |
Debt/Equity |
0.02 | 0.04 | 0.15 | 0.18 | |
Asset Turnover |
0.11 | 0.00 | 0.13 | 0.13 | |
Operating CF/Net income |
0.75 | — | 0.51 | 0.46 | |
Capex/Depreciation |
5.91 | — | (0.02) | (7.55) | |
Research and Development Expense of Revenue |
831.41% | — | 401.26% | 524.53% | |
Selling, General and Administrative Expense of Revenue |
738.22% | — | 391.48% | 544.15% | |
Intangible Assets out of Total Assets |
0.50 | 0.53 | 0.57 | 0.58 | |
Share Based Compensation of Revenue |
143.98% | — | 318.30% | 281.89% | |
Graham Net Nets |
0.01 | — | (0.08) | (0.08) | |
Graham Number |
0.00 | — | 0.00 | 0.00 | |
Earnings Yield |
(17.86%) | — | (28.85%) | (33.33%) | |
Free Cash Flow Yield |
(12.73%) | — | (18.47%) | (20.99%) | |
Revenue per Share |
0.00 | — | 0.00 | 0.00 | |
Operating CF per Share |
(0.01) | — | (0.01) | (0.01) | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.02) | — | (0.01) | (0.02) | |
Cash per Share |
0.01 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.09 | 0.00 | 0.06 | 0.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.09 | 0.00 | 0.06 | 0.06 | |
Free Cash Flow |
(1.57) | — | (1.22) | (1.77) | |
Working Capital |
0.49 | (0.37) | (1.73) | (1.95) | |
Capital Expenditures |
(0.21) | — | 0.00 | (0.42) | |
Net Current Asset Value |
0.35 | (0.50) | (1.92) | (2.10) | |
EV/EBIT |
0.00 | — | 0.00 | 0.00 | |
Capex to Sales |
1.08 | — | 0.00 | 1.60 | |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.04 | 0.03 | 0.04 | 0.07 | |
Average Payables |
0.70 | 0.92 | 1.07 | 1.28 | |
Average Inventory |
1.08 | 1.04 | 1.00 | 0.99 | |
Average Assets |
10.06 | 9.40 | 8.97 | 8.72 | |
Average Common Equity |
7.73 | 6.84 | 6.23 | 6.11 |
Columns are period end dates · fundamentals updated 5 Oct 2026